专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050058633A1 Stem cells that transform to beating cardiomyocytes 失效
标题翻译：转化为心跳肌细胞的干细胞
公开(公告)号：US20050058633A1
公开(公告)日：2005-03-17
申请号：US10863004
申请日：2004-06-07
申请人： Neal Epstein , Thiru Gopal , Steve Winitsky , Shahin Hassanzadeh
发明人： Neal Epstein , Thiru Gopal , Steve Winitsky , Shahin Hassanzadeh
IPC分类号： G01N33/48 , A61K35/12 , A61K35/34 , A61L27/00 , A61P9/00 , A61P9/10 , A61P21/00 , C12N5/02 , C12N5/077 , C12N5/10 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50 , A61K48/00 , C12N5/06 , C12N5/08 , C12N15/86
CPC分类号： G01N33/5073 , A61K35/12 , A61K35/34 , C12N5/0657 , C12N5/0662 , C12N2500/25 , C12N2501/11 , C12N2501/115 , C12N2503/02
摘要： Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
摘要翻译：本文公开了一种新颖的分离的干细胞群，称为spoc细胞，其可以在体内或体外诱导分化成心肌细胞。本文公开了分化孢子细胞的方法，并利用这些spoc细胞用于影响心肌细胞的筛选试剂。本文还提供了用于治疗应用中的spoc细胞用于治疗心肌缺陷如局部缺血或创伤性损伤的方法。

2. 发明授权

US07375185B2 Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use 失效
标题翻译：心肌肌球蛋白轻链激酶多肽，编码核酸和使用方法
公开(公告)号：US07375185B2
公开(公告)日：2008-05-20
申请号：US10380236
申请日：2001-09-12
申请人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
发明人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
IPC分类号： C07K1/00
CPC分类号： C12N9/1205 , A01K2217/075 , A61K38/00 , C12N2799/026
摘要： The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
摘要翻译：本公开提供肌球蛋白轻链激酶（cMLCK）的人心脏同种型的cDNA，蛋白质序列和基因组结构，并描述与心脏功能障碍相关的cMLCK基因中的突变。提供了用于鉴定可以在cMLCK基因中存在突变的个体的携带方法，或携带可将它们倾向于心脏功能障碍的等位基因。还公开了cMLCK调节心脏收缩力的重要作用。本文显示了cMLCK蛋白以减少拉伸活化的幅度并增加张力产生，这是迄今在心脏收缩中未知作用的肌肉的性质。此外，cMLCK蛋白质显示在区域分布在心脏中，从而对收缩性和拉伸活化具有不同的影响。提供本文的方法以利用cMLCK的这种作用来治疗患有或易于发生心脏功能障碍的个体。此外，提供了用于鉴定调节cMLCK活性的药剂的方法，从而在治疗心脏功能障碍中具有潜在的治疗重要性。

3. 发明申请

US20070212423A1 STEM CELLS THAT TRANSFORM TO BEATING CARDIOMYOCYTES 审中-公开
标题翻译：干细胞转化为骨质疏松症
公开(公告)号：US20070212423A1
公开(公告)日：2007-09-13
申请号：US11747060
申请日：2007-05-10
申请人： Neal Epstein , Thiru Gopal , Steve Winitsky , Shahin Hassanzadeh
发明人： Neal Epstein , Thiru Gopal , Steve Winitsky , Shahin Hassanzadeh
IPC分类号： A61K35/34 , C12N5/02 , C12Q1/02
CPC分类号： G01N33/5073 , A61K35/12 , A61K35/34 , C12N5/0657 , C12N5/0662 , C12N2500/25 , C12N2501/11 , C12N2501/115 , C12N2503/02
摘要： Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
摘要翻译：本文公开了一种新颖的分离的干细胞群，称为spoc细胞，其可以在体内或体外诱导分化成心肌细胞。本文公开了分化孢子细胞的方法，并利用这些spoc细胞用于影响心肌细胞的筛选试剂。本文还提供了用于治疗应用中的spoc细胞用于治疗心肌缺陷如局部缺血或创伤性损伤的方法。

4. 发明授权

US07220582B2 Stem cells that transform to beating cardiomyocytes 失效
标题翻译：转化为心跳肌细胞的干细胞
公开(公告)号：US07220582B2
公开(公告)日：2007-05-22
申请号：US10863004
申请日：2004-06-07
申请人： Neal D. Epstein , Thiru V. Gopal , Steve O. Winitsky , Shahin Hassanzadeh
发明人： Neal D. Epstein , Thiru V. Gopal , Steve O. Winitsky , Shahin Hassanzadeh
IPC分类号： C12N5/02
CPC分类号： G01N33/5073 , A61K35/12 , A61K35/34 , C12N5/0657 , C12N5/0662 , C12N2500/25 , C12N2501/11 , C12N2501/115 , C12N2503/02
摘要： Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
摘要翻译：本文公开了一种新颖的分离的干细胞群，称为spoc细胞，其可以在体内或体外诱导分化成心肌细胞。本文公开了分化孢子细胞的方法，并利用这些spoc细胞用于影响心肌细胞的筛选试剂。本文还提供了用于治疗应用中的spoc细胞用于治疗心肌缺陷如局部缺血或创伤性损伤的方法。

5. 发明申请

US20080095743A1 Monoclonal Antibody that Specifically Binds Stem Cells and its Use 审中-公开
标题翻译：特异性结合干细胞的单克隆抗体及其用途
公开(公告)号：US20080095743A1
公开(公告)日：2008-04-24
申请号：US11578891
申请日：2005-04-25
申请人： Neal Epstein , Steve Winitsky , Thiru Gopal , Shahin Hassanzadeh
发明人： Neal Epstein , Steve Winitsky , Thiru Gopal , Shahin Hassanzadeh
IPC分类号： A61K48/00 , A61P25/00 , C12N5/02 , C12N5/04 , G01N33/53
CPC分类号： G01N33/56966
摘要： Antibodies are disclosed herein that bind Spoc cells. In one embodiment the antibodies are monoclonal antibodies. The use of antibodies that bind Spoc cells to identify and/or isolate a sub-population of Spoc cells is also disclosed. In one embodiment, a method for treating a neurologic disorder is provided. The method includes administering a sub-population of Spoc cells and/or and neuronal cells differentiated from Spoc cells to treat a neurologic disorder.
摘要翻译：本文公开了结合Spoc细胞的抗体。在一个实施方案中，抗体是单克隆抗体。还公开了使用结合Spoc细胞鉴定和/或分离Spoc细胞亚群的抗体。在一个实施方案中，提供了治疗神经障碍的方法。该方法包括施用Spoc细胞的亚群和/或从Spoc细胞分化的神经元细胞以治疗神经系统疾病。

6. 发明授权

US07824682B2 Cardiac myosin light chain kinase-specific antibodies and methods of detecting 失效
标题翻译：心肌肌球蛋白轻链激酶特异性抗体及检测方法
公开(公告)号：US07824682B2
公开(公告)日：2010-11-02
申请号：US12101812
申请日：2008-04-11
申请人： Neal D. Epstein , Shahin Hassanzadeh , Steve O. Winitsky , Julien S. Davis
发明人： Neal D. Epstein , Shahin Hassanzadeh , Steve O. Winitsky , Julien S. Davis
IPC分类号： A61K39/395 , C07K16/40 , G01N33/53
CPC分类号： C12N9/1205 , A01K2217/075 , A61K38/00 , C12N2799/026
摘要： The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
摘要翻译：本公开提供肌球蛋白轻链激酶（cMLCK）的人心脏同种型的cDNA，蛋白质序列和基因组结构，并描述与心脏功能障碍相关的cMLCK基因中的突变。提供了用于鉴定可以在cMLCK基因中存在突变的个体的携带方法，或携带可将它们倾向于心脏功能障碍的等位基因。还公开了cMLCK调节心脏收缩力的重要作用。本文显示了cMLCK蛋白以减少拉伸活化的幅度并增加张力产生，这是迄今在心脏收缩中未知作用的肌肉的性质。此外，cMLCK蛋白质显示在区域分布在心脏中，从而对收缩性和拉伸活化具有不同的影响。提供本文的方法以利用cMLCK的这种作用来治疗患有或易于发生心脏功能障碍的个体。此外，提供了用于鉴定调节cMLCK活性的药剂的方法，从而在治疗心脏功能障碍中具有潜在的治疗重要性。

7. 发明申请

US20080274994A1 CARDIAC MYOSIN LIGHT CHAIN KINASE AND METHODS OF USE 失效
公开(公告)号：US20080274994A1
公开(公告)日：2008-11-06
申请号：US12101812
申请日：2008-04-11
申请人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
发明人： Neal D. Epstein , Shahin Hassanzadeh , Steven Winitsky , Julien S. Davis
IPC分类号： A61K31/7088 , C12Q1/68 , C12N15/55 , C12N15/85 , C12N5/10 , C07K16/40 , A61P9/04
CPC分类号： C12N9/1205 , A01K2217/075 , A61K38/00 , C12N2799/026
摘要： The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
摘要翻译：本公开提供肌球蛋白轻链激酶（cMLCK）的人心脏同种型的cDNA，蛋白质序列和基因组结构，并描述与心脏功能障碍相关的cMLCK基因中的突变。提供了用于鉴定可以在cMLCK基因中存在突变的个体的携带方法，或携带可将它们倾向于心脏功能障碍的等位基因。还公开了cMLCK调节心脏收缩力的重要作用。本文显示了cMLCK蛋白以减少拉伸活化的幅度并增加张力产生，这是迄今在心脏收缩中未知作用的肌肉的性质。此外，cMLCK蛋白质显示在区域分布在心脏中，从而对收缩性和拉伸活化具有不同的影响。提供本文的方法以利用cMLCK的这种作用来治疗患有或易于发生心脏功能障碍的个体。此外，提供了用于鉴定调节cMLCK活性的药剂的方法，从而在治疗心脏功能障碍中具有潜在的治疗重要性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式